UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037225
Receipt number R000042442
Scientific Title A prospective randomized controlled trial of the usefulness of the bispectral index (BIS) monitor in propofol sedation with double-balloon endoscopic retrograde cholangiopancreatography (DB-ERCP) for postoperative reconstructed intestinal cases
Date of disclosure of the study information 2019/07/01
Last modified on 2020/07/03 17:33:34

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A prospective randomized controlled trial of the usefulness of the bispectral index (BIS) monitor in propofol sedation with double-balloon endoscopic retrograde cholangiopancreatography (DB-ERCP) for postoperative reconstructed intestinal cases

Acronym

A prospective randomized controlled trial of the usefulness of the bispectral index (BIS) monitor in propofol sedation with double-balloon endoscopic retrograde cholangiopancreatography (DB-ERCP) for postoperative reconstructed intestinal cases

Scientific Title

A prospective randomized controlled trial of the usefulness of the bispectral index (BIS) monitor in propofol sedation with double-balloon endoscopic retrograde cholangiopancreatography (DB-ERCP) for postoperative reconstructed intestinal cases

Scientific Title:Acronym

A prospective randomized controlled trial of the usefulness of the bispectral index (BIS) monitor in propofol sedation with double-balloon endoscopic retrograde cholangiopancreatography (DB-ERCP) for postoperative reconstructed intestinal cases

Region

Japan


Condition

Condition

patients with postoperative reconstructed intestine who are scheduled to be performed DB-ERCP

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In the sedation during DB-ERCP, we compare body movement occurrence rates in the group using and not using BIS monitor, and verify the usefulness of BIS monitor.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The body movement occurrence rates in each group

Key secondary outcomes

1)Occurrence rate of respiratory depression and circulatory failure in each group
2)Inspection interruption rate due to sedation failure in each group
3)Technical success rate in each group
4)Propofol dose in each group
5)Procedure time and anesthesia time in each group
6)Recovery time in each group
7)Risk factors for occurrence of body movement
8)Sedation satisfaction score
9)Adverse events


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Device,equipment

Interventions/Control_1

Using BIS monitor, consider BIS value: 40-60 as appropriate sedation level and adjust the target blood concentration of propofol.

Interventions/Control_2

Do not use BIS monitor, consider Ramsey Sedation Score: SS 5-6 as the appropriate sedation level and adjust the target blood concentration of propofol.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

patients with postoperative reconstructed intestine who are scheduled to be performed DB-ERCP

Key exclusion criteria

1)Patients less than 20 years old
2)Pregnant woman
3)Patients with egg, soy, propofol allergy
4)Patients with hypotension (less than 90/50 mmHg) or bradycardia (less than 50bpm), and patients receiving oxygen prior to sedation
5)Patients with ASA-Performance status 4-6
6)Patients already registered in this study
7)Patients who determined to be inappropriate

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Hironari
Middle name
Last name Kato

Organization

Okayama University Hospital

Division name

Division of Endoscopy

Zip code

700-8558

Address

2-5-1Shikata-cho,Kita-ku Okayama-city Okayama

TEL

086-235-7219

Email

drkatocha@yahoo.co.jp


Public contact

Name of contact person

1st name Kazuya
Middle name
Last name Miyamoto

Organization

Okayama University Hospital

Division name

Department of Gastroenterology and Hepatology

Zip code

700-8558

Address

2-5-1Shikata-cho,Kita-ku Okayama-city Okayama

TEL

086-235-7219

Homepage URL


Email

ttpcx442@yahoo.co.jp


Sponsor or person

Institute

Okayama University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital, Ethics Committee

Address

2-5-1Shikata-cho,Kita-ku Okayama-city Okayama

Tel

086-235-6938

Email

mae6605@adm.okayama-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 07 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2019 Year 07 Month 01 Day

Date of IRB

2019 Year 07 Month 01 Day

Anticipated trial start date

2019 Year 08 Month 20 Day

Last follow-up date

2021 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 07 Month 01 Day

Last modified on

2020 Year 07 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042442


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name